Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association

Journal of Clinical Lipidology

Volumn 11, Issue 4, 2017, Pages 880-890

  Orringer, Carl E ^a   Jacobson, Terry A ^b   Saseen, Joseph J ^c   Brown, Alan S ^d   Gotto, Antonio M ^e   Ross, Joyce L ^f   Underberg, James A ^g  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alirocumab; Dyslipidemia; Evolocumab; Familial hypercholesterolemia; Hypercholesterolemia; Lipid treatment guidelines; PCSK9 inhibitors; Statin intolerance

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE 9; PROPROTEIN CONVERTASE 9 INHIBITOR; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; PROTEINASE INHIBITOR;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL OUTCOME; CLINICAL PRACTICE; CORONARY ARTERY ATHEROSCLEROSIS; DRUG HYPERSENSITIVITY; DRUG SAFETY; EVIDENCE BASED PRACTICE; FAMILIAL HYPERCHOLESTEROLEMIA; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; INTRAVASCULAR ULTRASOUND; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; ADULT; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; BLOOD; CLINICAL TRIAL (TOPIC); EVIDENCE BASED MEDICINE; EXPERT WITNESS; GENETICS; HOMOZYGOTE; MEDICAL SOCIETY; RISK;

ADULT; ATHEROSCLEROSIS; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; EXPERT TESTIMONY; HOMOZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PHENOTYPE; PROPROTEIN CONVERTASE 9; PROTEASE INHIBITORS; RISK; SOCIETIES, MEDICAL;

EID: 85019880943     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2017.05.001     Document Type: Article

References (23)

1. Jacobson, T.A., Maki, K.C., Orringer, C.E., et al. National Lipid Association Recommendations for the Patient-Centered Management of Dyslipidemia: Part 2. J Clin Lipidol 9 (2015), S1–S122.
2. Tavori, H., Fan, D., Blakemore, J.L., et al. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation 127 (2013), 2403–2413.
3. Urban, D., Poss, J., Bohm, M., et al. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol 62 (2013), 1401–1408.
4. Robinson, J.G., Farnier, M., Krempf, M., et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372 (2015), 1489–1499.
5. Sabatine, M.S., Giugliano, R.P., Wiviott, S.D., et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372 (2015), 1500–1509.
6. Nicholls, S.J., Puri, R., Anderson, T., et al. Effect of evolocumab on progression of coronary disease in statin-treated patients. The GLAGOV randomized clinical trial. JAMA 316 (2016), 2373–2384.
7. Sabatine, M.S., Giugliano, R.P., Keech, A.C., et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376 (2017), 1713–1722.
8. Gugliano RP, Mach F, Zavitz K, et al. Primary results of EBBINGHAUS, a cognitive study of patients enrolled in the FOURIER trial. American College of Cardiology 2017 Scientific Sessions; March 18, 2017; Washington DC. Abstract 17-LB-16161-AC.
9. Robinson, J.G., Rosenson, R.S., Farnier, M., et al. Safety of very low density lipoprotein cholesterol values with alirocumab. J Am Coll Cardiol 69 (2017), 471–482.
10. Khera, A.V., Won, H.H., Peloso, G.M., et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol 67 (2016), 2578–2589.
11. Gidding, S.S., Champagne, M.A., deFerranti, S.D., et al. The agenda for familial hypercholesterolemia. A statement from the American Heart Association. Circulation 132 (2015), 2167–2192.
12. Perak, A.M., Ning, H., de Ferranti, S.D., et al. Long-term risk of atherosclerotic cardiovascular disease in US adults with familial hypercholesterolemia phenotype. Circulation 134 (2016), 9–19.
13. Robinson, J.G., Huijgen, R., Ray, K., et al. Determining when to add non-statin therapy. J Am Coll Cardiol 68 (2016), 2412–2421.
14. Besseling, J., Hovingh, K., Hujjgen, R., et al. Statins in familial hypercholesterolemia. Consequences for coronary artery disease and all-cause mortality. J Am Coll Cardiol 68 (2016), 252–260.
15. Nanchen, D., Gencer, B., Muller, O., et al. Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes. Circulation 134 (2016), 698–709.
16. Kastelein, J.P., Ginsberg, H.N., Langslet, G., et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolemia. Eur Heart J 36 (2015), 2996–3003.
17. Raal, F.J., Stein, E.A., Dufour, R., et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolemia (RUTHERFORD-2): a randomised double-blind, placebo-controlled trial. Lancet 385 (2015), 331–340.
18. Moriarty, P.M., Parhofer, K.G., Babirak, S.P., et al. Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J 37 (2016), 3588–3595.
19. Ridker, P.M., Revkin, J., Amerenco, P., et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med 376 (2017), 1527–1539.
20. Raal, F.J., Honarpour, N., Blom, D.J., et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolemia (TESLA Part B): a randomized, double-blind, placebo-controlled trial. Lancet 381 (2015), 341–350.
21. Cuchel, M., Bruckert, E., Ginsberg, H.N., et al. Homozygous familial hypercholesterolemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolemia of the European Atherosclerosis Society. Eur Heart J 35 (2014), 2146–2157.
22. Nissen, S.E., Stroes, E., Dent-Acosta, R.E., et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance. The GAUSS-3 randomized clinical trial. JAMA 315:15 (2016), 1580–1590.
23. Serban, M.-C., Colantonio, L.D., Manthripragada, A.D., et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol 69 (2017), 1386–1395.